One of the most consumed probiotic bacteria, with a long record of safe use. The best evidence supports easing the diarrhea that follows antibiotics and modestly shortening common infections; moderate support for bowel regularity. Inexpensive and well tolerated. Serious infection risk applies only to seriously ill or immune-weakened people. Benefits are strain-specific. (Full Review)

Protocol

Dose

1–100 billion CFU/day

Once-daily dosing is standard and sufficient

Format

Drink, yogurt, or capsule

Capsules suit those avoiding dairy or sugar

Timing

With or before a meal

Morning with breakfast; consistency matters most

Time to effect

Infection defense

Weeks

Builds over consistent daily use

Regularity

1–2 weeks

Digestive regularity and tolerance changes

Metabolic markers

8–12 weeks

Effects are gradual and modest

Benefits

High: Prevention of antibiotic-associated diarrhea; reduced incidence of common infections

Medium: Relief of functional constipation; adjunct to Helicobacter pylori eradication

Low: Modest metabolic improvements; irritable bowel syndrome symptom relief

Speculative: Colorectal cancer risk modulation; mood and stress resilience; healthy aging and longevity

Contraindications

Severe immunosuppression (neutropenia <500 cells/µL, active chemotherapy, transplant recipients, advanced untreated HIV)

Critical illness or ICU care

Central venous catheter in place

Short bowel syndrome

Damaged or prosthetic heart valves (endocarditis risk)

Key Interactions

Oral antibiotics (amoxicillin, azithromycin, ciprofloxacin)

Immunosuppressant drugs (ciclosporin, tacrolimus, corticosteroids, chemotherapy)

Antifungal agents (in immunocompromised patients)

Risk & Side Effects

High: Mild digestive symptoms

Low: Systemic infection in vulnerable individuals

Speculative: Delayed microbiome recovery after antibiotics; D-lactic acidosis

Monitoring

Marker	Target	Why
hs-CRP	< 1.0 mg/L	Tracks systemic inflammation the strain may modestly lower
Fasting glucose	70–85 mg/dL	Detects any small glycemic effect in at-risk users
HbA1c	< 5.4%	Reflects longer-term average blood sugar
LDL cholesterol	< 100 mg/dL	Captures any bile-acid-mediated cholesterol change
Fecal calprotectin	< 50 µg/g	Gauges intestinal inflammation for gut-focused use

Cadence: Recheck relevant markers at 8–12 weeks, then every 6–12 months or if symptoms change

Qualitative Assessment

Bowel regularity and stool consistency
Bloating, gas, and general digestive comfort
Frequency and duration of common colds or gut infections
Overall energy and sense of well-being
Tolerance of the product itself

Lactobacillus casei for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment